TLDR
- Huma acquires Aluna, a U.S.-based respiratory monitoring company
- Partnership formed with Eckuity Capital to drive M&A strategy
- Aluna’s solutions will be relaunched on Huma Cloud Platform with FDA Class II upgrade
- Huma extends reach to over 150 U.S. health systems, serving approximately 500,000 contracted lives
- Acquisition strengthens Huma’s position in respiratory health market with 25 million asthma and 15 million COPD patients in the U.S.
Huma Therapeutics, a global healthcare AI leader, has announced two major developments that will expand its digital healthcare ecosystem.
The company has acquired Aluna, a U.S.-based company specializing in respiratory disease monitoring, and formed a partnership with investment firm Eckuity Capital to accelerate its merger and acquisition strategy.
The announcements were made on May 16, 2025, marking what Huma’s Founder and CEO Dan Vahdat called “a new chapter” for the company. Vahdat stated that these moves are part of Huma’s mission to build “the most impactful healthcare company in the world.”
Huma’s disease-agnostic cloud platform has earned major regulatory certifications, including FDA 510(k) Class II and EU MDR Class IIb status. The platform currently supports over 4,500 hospitals and clinics across more than 70 countries, engaging over 50 million individuals worldwide.
The acquisition of Aluna expands Huma’s footprint in the respiratory health sector. Based in San Francisco, Aluna specializes in respiratory patient monitoring and manufactures proprietary peak flow meters.
Strategic Partnership Fuels Growth
The partnership with Eckuity Capital is designed to provide resources for Huma’s aggressive M&A strategy. The company aims to acquire complementary businesses to build a comprehensive digital ecosystem supporting healthcare providers, pharmaceutical companies, and patients worldwide.
Youssef Sebban, Managing Partner at Eckuity Capital, explained their approach:
“We help Huma acquire companies that, on their own, may not fully realize their potential but when integrated into Huma’s cloud platform, become highly complementary and transformative.”
The collaboration is expected to amplify the impact of acquired companies on the healthcare ecosystem while driving value creation for investors and shareholders. Eckuity Capital, with offices in New York and London, focuses on solutions that improve productivity, efficacy, and efficiency across healthcare.
Enhancing Respiratory Care Capabilities
The Aluna acquisition brings more than 150 U.S.-based health systems and clinic networks into Huma’s global network. This significantly strengthens Huma’s position in the respiratory health market, which includes more than 25 million asthma patients and 15 million COPD patients in the United States alone.
Aluna’s solutions will be relaunched on the Huma Cloud Platform, which enables seamless, code-free configuration and AI/ML integration across various disease areas. The integration will elevate Aluna’s product classification to FDA Class II, providing greater clinical value for patients and providers.
Existing Aluna customers will gain access to Huma’s comprehensive portfolio of disease management programs. These span asthma, COPD, sleep apnea, and related conditions, serving approximately 500,000 contracted lives.
Charvi Shetty, CEO of Aluna, expressed enthusiasm about the acquisition:
“Joining forces with Huma offers a chance to amplify our impact and extend the reach of our AI-driven respiratory management platform to a wider patient base worldwide.”
Aluna’s technology incorporates a portable, FDA-cleared spirometer, a mobile application, and a clinician portal. The system enables real-time tracking of lung function and respiratory health, making it valuable for managing conditions like asthma, COPD, and cystic fibrosis.
Vishal Jain, Managing Partner at Eckuity Capital, praised Huma’s vision: “The AI-led transformation of care that we will witness over the next two decades needs a reliable, real-time, and responsive infrastructure that very few companies can offer globally, and Huma is one of the most capable companies that can deliver on this promise.”
Goodwin Proctor served as the exclusive legal advisor to Huma on the Aluna transaction, while Peak Technology Partners acted as the exclusive financial advisor to Aluna.
Huma continues to play a key role in national healthcare initiatives across the U.S., U.K., Germany, Greece, and Saudi Arabia. The company partners with leading health systems, pharmaceutical companies, and clinical research organizations to transform healthcare delivery worldwide.
The acquisition of Aluna and partnership with Eckuity Capital position Huma to deliver greater value to healthcare providers and patients through its expanded digital healthcare ecosystem.
